Why Specialty Lab Samples Are So Vulnerable To Trial Execution Errors

Biomarker and other specialty lab samples are among the most fragile parts of clinical trial execution. They can be critical to study interpretation, yet too many patient contributions are put at risk before they ever make it into the dataset.

In this short webinar excerpt, Nancy Valente, M.D., and Dr. Richard Graham discuss why specialty lab samples are so vulnerable to mishandling and why the industry must do better to protect both patients and data integrity.